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Background: The telomeric 3′-overhang (G-tail) length is essential for the biological effects of telomere
dysfunction in vitro, but the association of length with aging and cardiovascular risk is unclear in humans. We
investigated the association between the telomere G-tail length of leukocytes and cardiovascular risk, age-
related white matter changes (ARWMCs), and endothelial function.
Methods: Patients with a history of cerebrovascular disease and comorbidity were enrolled (n = 102; 69 males
and 33 females, 70.1 ± 9.2 years). Total telomere and telomere G-tail lengths were measured using a hybridiza-
tion protection assay. Endothelial function was evaluated by ultrasound assessment of brachial ﬂow-mediated
dilation (FMD).
Findings: Shortened telomere G-tail length was associated with age and Framingham risk score (P = 0.018 and
P = 0.012). In addition, telomere G-tail length was positively correlated with FMD values (P = 0.031) and
negatively with the severity of ARWMCs (P= 0.002). Onmultivariate regression analysis, telomere G-tail length
was independently associated with FMD values (P = 0.022) and the severity of ARWMCs (P= 0.033), whereas
total telomere length was not associated with these indicators.
Interpretation: Telomere G-tail length is associated with age and vascular risk factors, and might be superior to
total telomere length as a marker of endothelial dysfunction and ARWMC severity.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Telomeres are the structures which cap each end of a chromatid, at
the extreme end of chromosomal deoxyribonucleic acid (DNA).
Telomeres are composed of a variable number of tandem repeats of
the sequence TTAGGG that extend over several thousand base pairs
(Blackburn, 2001). The protected state of telomeres is necessary to safe-
guard the integrity of genomicmaterial. Telomere length is considered aa biomarker of human aging;
sclerosis. Recently, the telomere
tranded 3′-overhang, has been
from DNA damage. We found
elomere length as a marker of
changes among patients with
ible for dementia, stroke and
e in general populations.
Molecular Biology, Institute of
, 1-2-3 Kasumi, Minami-ku,
. This is an open access article underbiomarker of human aging, namely an indicator of oxidative stress and
cellular senescence (von Zglinicki andMartin-Ruiz, 2005). Additionally,
telomere shortening in leukocytes is correlatedwith atherosclerosis and
cardiovascular aging (DeMeyer et al., 2011; Butt et al., 2010; Khan et al.,
2012). Telomeric DNA is shielded by telomere binding-speciﬁc proteins,
such as the ‘shelterin complex’, which bind to and protect the terminal
loop (t-loop) of telomeres (Bailey et al., 2001; de Lange, 2005). Telo-
meres are composed of double-stranded repeated DNA with terminal
3′ single-stranded G-rich overhangs called telomere G-tails. The telo-
mere G-tail folds back to form a t-loop, which prevents the end of the
telomere from being recognized as a damaged, broken end. Telomere
G-tails are thus key structures that protect telomere DNA from DNA
damage. Indeed, the telomere G-tail is thought to be a more important
factor in chromosome maintenance than total telomere length (Tsai
et al., 2007; Anno et al., 2007). However, the association of telomere
G-tail length with various cardiovascular risk factors in humans has
not been clariﬁed. To our knowledge, only one report has shown an as-
sociation between the telomere G-tail and cardiovascular events in he-
modialysis patients (Hirashio et al., 2014).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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atherosclerosis. Impairment of endothelial function is an important
ﬁrst step in the pathogenesis of atherosclerosis, and is associated with
an insufﬁcient endothelial repair mechanism for vascular injury
(Deanﬁeld et al., 2007). Ultrasound assessment of brachial artery ﬂow-
mediated dilation (FMD), a useful noninvasive method, has been used
as an index of endothelium-dependent vasodilation. Several studies
have reported that FMD is impaired in patients with coronary disease
and cardiovascular risk factors. In addition, impaired FMD is associated
with the severity of age-related white matter changes (ARWMCs)
(Hoth et al., 2007). However, the association of telomere G-tail length
with endothelial dysfunction and ARWMCs remains unclear.
Here, we investigated associations among telomere G-tail length in
leukocytes, aging, vascular risk factors and endothelial dysfunction in
patients with chronic cerebrovascular disease and comorbidities.
2. Methods
2.1. Study Participants
The study was conducted under a single-center, hospital-based pro-
spective design. The study protocol was governed by the guidelines of
the Japanese government, based on the Helsinki Declaration as revised
in 1983. The study was approved by the Institutional Research and
Ethics Committee of our hospital. All patients provided written
informed consent to participate. Patients treated for cerebrovascular
disease (at least 6 months after stroke onset) or atypical neurological
problems (e.g., dizziness, headache, numbness and other symptoms)
at Hiroshima University Hospital between November 2012 and April
2014 were enrolled. All patients underwent magnetic resonance imag-
ing (MRI) and FMD studies, with the MRI study performed within
3 months before or after the FMD study. Baseline clinical characteristics
were recorded, including age, sex, hypertension, diabetes mellitus,
dyslipidemia, atrial ﬁbrillation, renal dysfunction, history of stroke
(ischemic or hemorrhagic), coronary artery disease and current
smoking status. In addition to obtaining a medical history, relevant
risk factors were identiﬁed from the self-reported medical history or
were inferred from medications prescribed by the primary physician.
The criteria for hypertension, diabetes mellitus and dyslipidemia
were as previously deﬁned (Hosomi et al., 2012). Framingham risk
score was calculated according to the presence of the following car-
diovascular risk factors: age, sex, total cholesterol level, high-density
lipoprotein cholesterol level, systolic blood pressure (treated or not
treated), diabetes mellitus and smoking status (D'Agostino et al.,
2008). Renal function was calculated using the estimated glomerular
ﬁltration rate (eGFR) with a revised equation for the Japanese popu-
lation, as follows: eGFR (ml/min/1.73 m2) = 194 × (serum
creatinine)−1.094 × (age)−0.287 × 0.739 (for women) (Matsuo et al.,
2009). Renal dysfunction was deﬁned as an eGFR b60 ml/min/
1.73 m2. Serum high-sensitivity C-reactive protein (hs-CRP) was
measured using a CRP-Latex kit (Nissui Pharmaceutical Co. Ltd.,
Tokyo, Japan) according to the manufacturer's instructions. The
FMD study and blood sample collection were performed in the
morning on the same day. To enroll control subjects, blood samples
were obtained from 493 volunteers. From these, we selected control
subjects who were matched with our study participants for age and
sex, and ﬁnally assessed 102 samples for telomere G-tail and total
telomere lengths as control subjects.
2.2. FMD and Nitroglycerin-mediated Vasodilation (NMD)
The patients were requested to abstain from alcohol, smoking and
caffeine on the day of the FMD examination. The FMD examination
was conducted during the fasting state in the morning, and only drink-
ing water was given to the patients. Most medications taken by the pa-
tients were withheld, and only those deemed necessary (such asantithrombotic therapies) were administered, at the discretion of the
attending physician. The FMDwasmeasuredwith a high-resolution lin-
ear artery transducer that was coupled to computer-assisted analysis
software (UNEXEF38G, UNEX Co., Nagoya, Japan) as detailed previously
(Maruhashi et al., 2012; Iwamoto et al., 2012). Brieﬂy, the FMDprotocol
was as follows: a blood pressure cuff was placed around the forearm of
the patient. The brachial artery was scanned longitudinally 5–10 cm
above the elbow with a special probe holder (UNEX Co.) to ensure the
consistency of the B-mode image. The diameter of the artery was auto-
matically tracked, and the waveform of diameter changes over the
cardiac cycle was displayed in real time using the FMD mode of the
tracking system. A baseline longitudinal image of the artery was
acquired for 30 s, and the blood pressure cuff was inﬂated to
50 mm Hg above systolic pressure for 5 min. Pulsed Doppler velocity
signals were obtained for 20 s at baseline and for 10 s immediately
after cuff deﬂation. Changes in the diameter of the brachial artery
were immediately expressed as thepercent change relative to the vessel
diameter before cuff inﬂation. The FMDwas automatically calculated as
the percent change in peak vessel diameter from the baseline value, and
%FMD (peak diameter − baseline diameter / baseline diameter) was
used for analysis. The nitroglycerin response was used to measure
endothelium-independent vasodilation. After acquiring a baseline rest-
ing image for 30 s, a 75-μg tablet of nitroglycerin was administered
sublingually, and images of the artery were recorded continuously for
8 min. The NMD was automatically calculated as the percent change
in peak vessel diameter from the baseline value, and %NMD (peak
diameter− baseline diameter / baseline diameter) was used for analy-
sis. A single investigator (T.N.) who was unaware of the clinical details
of the patient performed the FMD and NMD evaluations for all patients.
The intra-observer coefﬁcients of variation were 1.2% for baseline
brachial artery diameter among all patients and 11.1% for FMD in 18
randomly selected patients.
2.3. Magnetic Resonance Imaging
MRI was performedwith a 1.5T scanner (Signa, GEMedical Systems,
Fairﬁeld, CT, USA orMagneton SymphonyAdvanced or Avanto, Siemens
Medical Systems, Erlangen, Germany) or 3.0T scanner (Signa, GE
Medical Systems). The imaging protocol consisted of a T1-weighted
spin-echo and a T2-weighted spin-echo and ﬂuid-attenuated inversion
recovery (FLAIR). A single stroke neurologist (T.N.)whowas unaware of
the clinical details of the patients graded the severity of the ARWMCs.
The severity of ARWMCs was rated visually from the FLAIR images
using the Fazekas scale (grade 0, no lesions; grade 1, punctate lesions;
grade 2, early conﬂuent lesions; and grade 3, conﬂuent lesions)
(Fazekas et al., 1987). Deepwhitematter changes (frontal, temporal, pa-
rietal, occipital) were assessed using the Scheltens scale score (score of
0 to 6: 0, absent; 1, b3 mm in ≤5 lesions; 2, b3 mm in ≥6 lesions; 3,
4–10 mm in ≤5 lesions; 4, 4–10 mm in ≥6 lesions; 5, ≥11 mm; and 6,
conﬂuent), giving a possible range of 0–24. Periventricular white
matter changes (frontal caps, lateral bands, occipital caps) (range,
0–6) were assigned scores of 0 to 2 (0, absent; 1, b5 mm; and 2,
5–10 mm) (Scheltens et al., 1993; Miwa et al., 2014). The sum of
these ratings was used as the Scheltens rating score (range, 0–30). The
Scheltens rating score was positively correlated with the Fazekas rating
scores (ρ 0.849, P b 0.001).
2.4. Measurement of Leukocyte Total Telomere Length and Telomere G-tail
Length
Peripheral blood samples were collected after FMD examination in
each patient. Total telomere length was measured using telomere
hybridization protection assay (HPA) methods (Hirose et al., 1997),
and telomere G-tail length was measured using a telomere G-tail HPA
(Tahara et al., 2005). Procedures are described in detail elsewhere
(Anno et al., 2007; Tahara et al., 2005). Brieﬂy, genomic DNA was
Table 1
Baseline characteristics.
n = 102
Age (years) 70.1 ± 9.2
Male 69 (67.6)
Body mass index (kg/m2) 22.8 ± 3.0
Smoker 8 (7.8)
Hypertension 72 (70.6)
Diabetes mellitus 30 (29.4)
Dyslipidemia 63 (61.8)
Atrial ﬁbrillation 15 (14.7)
Renal dysfunction 34 (33.3)
Systolic blood pressure (mm Hg) 132.0 ± 20.2
Diastolic blood pressure (mm Hg) 77.8 ± 12.8
History of stroke 72 (70.6)
History of coronary artery disease 10 (9.8)
Framingham risk scores 16 (13–18.3)
Physiological ﬁndings
FMD (%) 4.25 ± 2.15
NMD (%) 13.30 ± 5.04
MRI ﬁndings (ARWMCs)
Fazekas rating scores 1 (1–2)
Scheltens rating scores 13 (7–18.3)
Laboratory ﬁndings
White blood cell (103/μl) 5.78 ± 1.93
HbA1c (%) 5.95 ± 0.75
FBG (mg/dl) 111.8 ± 24.3
LDL cholesterol (mg/dl) 109.4 ± 26.3
HDL cholesterol (mg/dl) 63.9 ± 21.3
TG (mg/dl) 105.6 ± 46.1
eGFR (ml/min/1.73 m2) 66.9 ± 17.5
Telomere G-tail length (RLU/μg DNA) 13653.0 ± 2787.4
Total telomere length (RLU/μg DNA) 176698.3 ± 20308.0
The data are presented as the means ± SD for age, body mass index, systolic blood pres-
sure, diastolic bloodpressure, FMD, NMDand laboratoryﬁndings; themedians (interquar-
tile ranges) for Framingham risk scores, Fazekas rating scale and Scheltens rating scale;
and the number (%) of patients.
FMD, ﬂow-mediated dilation; NMD, nitroglycerin-mediated dilation; MRI, magnetic
resonance imaging; ARWMCs, age-related white matter changes; FBG, fasting blood glu-
cose; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides;
eGFR, estimated glomerular ﬁltration rate; RLU, relative light unit; DNA, deoxyribonucleic
acid.
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method. The amount of DNA used in each assay was measured before
assay using a Nanophotometer Pearl (Implen GmbH, Munich,
Germany) with an AE-labeled telomere probe (Fujirebio Inc., Tokyo,
Japan). G-tail telomere length was measured using 1 μg of non-
denatured genomic DNA, and total telomere length was measured
using 0.2 μg of denatured genomic DNA using a 96-plate formatted
automated machine, JANUS® Automated Workstation, combined with
an EnVision® Multilabel Plate Reader (PerkinElmer, Massachusetts
U.S.A.). All samples were assessed in triplicate, with genomic DNA of
HeLa cells used as control to correct for inter-assay variability. The aver-
age coefﬁcient of variance in all samples was 4.8% for telomere G-tail
length and 4.8% for total telomere length, while the inter-assay coefﬁ-
cient of variance was 6.2% for telomere G-tail length and 6.1% for total
telomere length.
2.5. Statistical Analysis
Statistical analysiswas performed using JMP 10.0 statistical software
(SAS Institute Inc., USA). The data are expressed as the mean ± stan-
dard deviation (SD) or median (25th and 75th percentiles) for continu-
ous variables and as frequency and percentage for discrete variables.
The patients were divided into tertiles, with the numbers of subjects
in order of telomere G-tail length or total telomere length (lowest
tertile, middle tertile and highest tertile). The statistical signiﬁcance of
inter-group differences was assessed by the χ2 test, unpaired t-test,
Mann–WhitneyU test and Kruskal–Wallis test, as appropriate. Relation-
ships between telomere G-tail length (or total telomere length) and the
other variables were examined by Spearman's correlation. In addition,
relationships among FMD, ARWMCs and the other variables were also
examined by Spearman's correlation. Indicators of the severity of endo-
thelial dysfunction (FMD values) or ARWMCs were identiﬁed using
multiple linear regression that included age, sex, body mass index,
smoking history, hypertension, diabetes mellitus, dyslipidemia, atrial
ﬁbrillation, renal dysfunction, systolic blood pressure, diastolic blood
pressure, history of stroke, history of coronary artery disease, laboratory
ﬁndings and telomere G-tail length or total telomere length by a back-
ward selection procedure using P N 0.10 for the likelihood ratio test as
exclusion criterion. Statistical signiﬁcance was established at P b 0.05.
3. Results
A total of 102 patients (69 males and 33 females, 70.1 ± 9.2 years)
were registered in the study. Baseline clinical characteristics are pre-
sented in Table 1. Telomere G-tail length was negatively correlated
with aging and positively correlated with total telomere length
(ρ−0.287, P = 0.004 and ρ 0.406, P b 0.001, Fig. 1). Neither telomere
G-tail length nor total telomere length was associated with laboratory
ﬁndings, including altered glucose levels, lipid levels, renal dysfunction
or inﬂammation (Supplemental Table 1). Patients in this study had a
shorter mean telomere G-tail length than control subjects (13653.0 ±
2787.4 RLU/μg DNA vs. 22504.9 ± 3249.1 RLU/μg DNA, P b 0.001), but
did not signiﬁcantly differ by total telomere length (Supplemental
Table 2). Further, the groups signiﬁcantly differed by distribution of
the association between age and telomere G-tail length (Fig. 1A), and
also signiﬁcantly differed in the distribution of associations with total
telomere length and telomere G-tail length (Fig. 1B).
3.1. Associations Between Telomere G-tail Length, Total Telomere Length
and Vascular Risk Factors
Associations between telomere G-tail length, total telomere length
and traditional vascular risk factors (hypertension, diabetes mellitus and
dyslipidemia) are presented in Fig. 2. Associations between total telomere
length and vascular risk factors were not signiﬁcantly different. In con-
trast, patients with diabetes mellitus had a shorter telomere G-tail lengththan those without (12755.4 ± 1831.2 RLU/μg DNA vs. 14027.0 ±
3025.8 RLU/μg DNA, P= 0.035). Patient characteristics according to telo-
mere G-tail length tertile are presented in Table 2. A shorter telomere G-
tail length (lowest tertile) was associatedwith age and a higher Framing-
ham risk score (P=0.018 andP=0.012). Similarly, total telomere length
(lowest tertile) was also associated with age and a higher Framingham
risk score (P = 0.001 and P = 0.026) (Supplemental Table 3).
3.2. Association Between Telomere G-tail Length, Total Telomere Length and
Endothelial Dysfunction
On univariate regression analysis, FMD was associated
with age (ρ −0.266, P = 0.007), male sex (ρ −0.309, P = 0.002),
BMI (ρ−0.255, P=0.010), hypertension (ρ−0.305, P=0.002), diabe-
tes mellitus (ρ−0.277, P = 0.005), renal dysfunction (ρ−0.208, P =
0.036), high-density lipoprotein cholesterol level (ρ 0.254, P = 0.010),
triglyceride level (ρ −0.280, P = 0.004), eGFR (ρ 0.199, P = 0.045)
and hs-CRP levels (ρ −0.224, P = 0.024) (Table 3). Telomere G-tail
length was positively correlated with FMD values (ρ 0.214, P =
0.031), whereas total telomere length was not signiﬁcantly associated
with FMD (ρ 0.112, P = 0.263) (Fig. 3A, B). Longer telomere G-tail
length was independently associated with FMD value (standardized
partial regression coefﬁcient [β] 0.205; P = 0.022) on multivariate
regression analysis for age, sex, comorbidity and other laboratory
ﬁndings (Table 3). In contrast, total telomere length was not associated
with FMD value on multivariate regression analysis using the
backward selection procedure. In addition, total telomere length was
not associated with FMD value after adjustment for age and sex (β
0.056; P = 0.574).
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Fig. 1. (A) Scatter plots representing the relationship between telomere G-tail length and age in patients and control subjects. (B) Scatter plots demonstrating the relationship between
telomere G-tail length and total telomere lengths in patients and control subjects.
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Fig. 2. Relationships among telomere G-tail length, total telomere length and vascular risk factors. *P b 0.05. HT = hypertension; DM= diabetes mellitus; DL = dyslipidemia.
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Table 2
Patient characteristics according to telomere G-tail length tertiles.
Telomere G tail lengths P
Lowest
tertile
(n = 34)
Middle
tertile
(n = 34)
Highest
tertile
(n = 34)
Age 72.6 ± 8.0 71.1 ± 7.7 66.6 ± 10.8 0.018
Male 22 (64.7) 22 (64.7) 25 (73.5) 0.668
Body mass index (kg/m2) 22.8 ± 3.6 22.7 ± 3.0 22.9 ± 2.4 0.947
Smoker 2 (5.9) 4 (11.8) 2 (5.9) 0.581
Hypertension 24 (70.6) 27 (79.4) 21 (61.8) 0.279
Diabetes mellitus 12 (35.3) 13 (38.2) 5 (14.7) 0.068
Dyslipidemia 22 (64.7) 23 (67.7) 18 (52.9) 0.418
Atrial ﬁbrillation 3 (8.8) 7 (20.6) 5 (14.7) 0.391
Renal dysfunction 14 (41.2) 9 (26.5) 11 (32.4) 0.433
Systolic blood pressure
(mm Hg)
132.1 ± 21.5 136.2 ± 20.9 127.9 ± 17.6 0.237
Diastolic blood pressure
(mm Hg)
75.2 ± 9.6 78.7 ± 16.4 79.5 ± 11.3 0.343
History of stroke 24 (70.6) 25 (73.5) 23 (67.7) 0.868
History of coronary
artery disease
4 (11.8) 2 (5.9) 4 (11.8) 0.642
Framingham risk scores 17 (11.8–20) 17 (15.5–18) 14 (11.8–16.3) 0.012
Physiological ﬁndings
FMD (%) 3.5 ± 1.5 4.4 ± 2.4 4.8 ± 2.4 0.044
NMD (%) 12.1 ± 4.0 14.1 ± 4.8 13.7 ± 6.0 0.224
MRI ﬁndings
Fazekas rating scores 2 (1–2) 1 (1–2) 1 (0–2) 0.357
Scheltens rating scores 16 (9.8–21.3) 12 (7.8–17.3) 10 (5–15.8) 0.036
The data are presented as the means ± SD for age, body mass index, systolic blood pres-
sure, diastolic blood pressure, FMD and NMD; the medians (interquartile ranges) for
Fazekas rating scores and Scheltens rating scores; and the number (%) of patients.
FMD, ﬂow-mediated dilation; NMD, nitroglycerin-mediated dilation; RLU, relative light
unit; DNA, deoxyribonucleic acid.
Table 3
Associations between vascular risk factors, laboratory ﬁndings andﬂow-mediated dilation
(FMD).
Flow-mediated dilation
Spearman's
correlation
Multiple linear
regression
ρ P β coefﬁcient P
Age −0.266 0.007 −0.229 0.016
Male −0.309 0.002 −0.233 0.010
Body mass index (kg/m2) −0.255 0.010 – –
Smoker −0.040 0.692 – –
Hypertension −0.305 0.002 −0.155 0.099
Diabetes mellitus −0.277 0.005 – –
Dyslipidemia −0.093 0.351 – –
Atrial ﬁbrillation 0.056 0.576 – –
Renal dysfunction −0.208 0.036 – –
Systolic blood pressure (mm Hg) −0.079 0.429 – –
Diastolic blood pressure (mm Hg) 0.082 0.415 – –
History of stroke −0.106 0.287 – –
History of coronary artery disease −0.095 0.344 – –
Laboratory ﬁndings
White blood cells (103/μl) −0.012 0.902 – –
HbA1c (%) −0.187 0.060 – –
FBG (mg/dl) −0.161 0.106 – –
LDL cholesterol (mg/dl) −0.045 0.650 – –
HDL cholesterol (mg/dl) 0.254 0.010 – –
TG (mg/dl) −0.280 0.004 −0.220 0.013
eGFR (ml/min/1.73 m2) 0.199 0.045 – –
hs-CRP, log (ng/ml) −0.224 0.024 – –
Telomere G-tail length (RLU/μg DNA) 0.214 0.031 0.205 0.022
β coefﬁcient means standardized partial regression coefﬁcient.
FBG, fasting blood glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
TG, triglycerides; eGFR, estimated glomerular ﬁltration rate; RLU, relative light unit;
DNA, deoxyribonucleic acid.
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and Age-related White Matter Changes
Univariate regression analysis revealed that the severity of ARWMCs
was associated with age (ρ 0.376, P b 0.001), hypertension (ρ 0.263,
P = 0.008), HbA1c level (ρ 0.215, P = 0.030) and fasting blood glucose
level (ρ 0.203, P = 0.041). Telomere G-tail length was negatively
correlated with the severity of ARWMCs (ρ −0.309, P = 0.002),
and total telomere length was slightly associated with ARWMCs
(ρ−0.210, P = 0.034) (Fig. 3C, D). In multivariate regression analysis,
shorter telomere G-tail length was independently associated with the
severity of ARWMCs (β −0.200; P = 0.033) (Table 4). In contrast,
total telomere length was associated with the severity of ARWMCs on
multivariate regression analysis using the backward selection proce-
dure. In addition, total telomere length was not associated with
ARWMCs after adjustment for age and sex (β−0.071; P = 0.476).
4. Discussion
In this study, we demonstrated that the telomere G-tail length of
leukocytes is signiﬁcantly correlated with the endothelial function and
severity of ARWMCs after adjustment for age, sex, traditional vascular
risk factors and laboratory ﬁndings. In contrast, no signiﬁcant associa-
tion was seen between the total telomere length of leukocytes and
these factors. Our study provides initial evidence for an association of
telomere G-tail length with aging, endothelial function and ARWMCs
in patients with vascular risk factors.
Several epidemiologic studies have demonstrated that shorter
leukocyte telomere length is associatedwith atherosclerosis and cardio-
vascular risk factors (Brouilette et al., 2003; Demissie et al., 2006). Thus,
the assessment of telomere length has been considered useful for the
prediction of progressive atherosclerosis or cardiovascular events (De
Meyer et al., 2011; Butt et al., 2010; Khan et al., 2012). Individuals
with shorter telomeres may have an increased risk of early vascular
cell aging and senescence, which causes progressive atherosclerosis.
On the other hand, inﬂammation, oxidative stress, and insulin resis-
tance, which are associated with cardiovascular disease, result in accel-
erated telomere attrition and shorter telomeres. Given that these
indicators are also associated with endothelial dysfunction, we and
others speculated that shorter telomeres might also be associated
with endothelial dysfunction. Minamino et al. reported that endothelial
senescence downstreamof telomere function inhibition is related to en-
dothelial dysfunction (increased intercellular adhesion molecule
[ICAM]-1 expression and decreased endothelial nitric oxide synthase
[eNOs] activity) in vitro (Minamino et al., 2002). Nakashima et al.
assessed the cardiovascular damage (CVD) score (hypertension,
dyslipidemia, diabetes, coronary artery disease, stroke and peripheral
artery disease), endothelial function using FMD, and leukocyte telomere
length by measuring mean telomere restriction fragment (TRF) length
using the Southern blot technique in patients with cardiovascular risk
factors (Nakashima et al., 2004). Although they found that CVD score
was associated with FMD and leukocyte telomere length, it was unclear
whether leukocyte telomere length was associated with FMD values. In
our study, total telomere length using telomere HPA methods was not
associated with endothelial function. Aged and hypertensive changes
of the brain (ARWMCs) appear as hyperintense foci on T2-weighted
MRI (Pantoni and Garcia, 1997). Patients with severe ARWMCs exhibit
an elevated long-term risk of stroke recurrence and unfavorable stroke
outcomes (Palumbo et al., 2007; Neumann-Haefelin et al., 2006). The
pathogenesis of ARWMCs is thought to be associated with endothelial
dysfunction. In addition, shorter leukocyte telomere length measured
using quantitative real-time polymerase chain reaction (PCR) was asso-
ciated with the severity of ARWMCs in non-demented community-
based subjects after adjustment for age, sex and some confounders
(Wikgren et al., 2014). In our study, the total telomere length of
leukocytes, as measured using telomere HPA methods, was slightly
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Fig. 3. (A) Scatter plots demonstrating the relationship between telomere G-tail length and ﬂow-mediated dilation (FMD). (B) Scatter plots demonstrating the relationship between total
telomere length and FMD. (C) Scatter plots demonstrating the relationship between telomere G-tail length and age-related white matter changes (ARWMCs). (D) Scatter plots demon-
strating the relationship between total telomere length and ARWMCs.
965T. Nezu et al. / EBioMedicine 2 (2015) 960–967associated with the severity of ARWMCs in univariate analysis. Howev-
er, the association between total telomere length and the severity of
ARWMCs was not signiﬁcant on multivariate analysis. The inconsis-
tencies between our present and these previous results might have
been due to differences in baseline characteristics, or in methods used
to measure telomere length and evaluate the severity of ARWMCs.
Compared with previous studies, the most interesting factor of our
study is its evaluation of telomere G-tail length. Associations between
telomere G-tail length and total telomere length have been studied in
human endothelial cells from umbilical cord veins (HUVEC) (Anno
et al., 2007). Here, we found that telomere G-tail length was positively
correlated with total telomere length in humans. However, it remained
unclear whether telomere G-tail length was a useful surrogate marker
of aging and cardiovascular risk factors in humans. Our study showed
that the distribution of associations between telomere G-tail length
and total telomere length were signiﬁcantly different from that in
control subjects. This different distributionmight indicate that telomere
G-tail length is more strongly inﬂuenced by cardiovascular risk factors
than is total telomere length. Recently, Hirashio et al. reported that
shorter telomere G-tail length was associated with future cardiovascu-
lar risk in hemodialysis patients, but that total telomere length did not
predict cardiovascular events (Hirashio et al., 2014). In addition, our
study demonstrated that telomere G-tail length is signiﬁcantly correlat-
ed with endothelial function and the severity of ARWMCs after adjust-
ment for age, sex and baseline characteristics, although the association
between total telomere length and these factors was not signiﬁcant.
This result supports the hypothesis that the telomere G-tail is a more
important factor in chromosome maintenance than total telomere
length in humans.This study has several limitations. First, our sample size was small,
and the causal relationship with leukocyte telomere G-tail length,
obtained from cross-sectional data, might be relatively weak. In addi-
tion, cross-sectional studies on the measurement of telomere length
are unable to evaluate the direct effect of time-dependent changes asso-
ciated with cardiovascular risk. A better understanding of whether the
rate of telomere G-tail length shortening differs from cardiovascular
risk and endothelial dysfunction will require longitudinal studies in a
larger number of patients. Second, the telomere HPA method is not
commonly used, and TRF analysis by Southern blot remains the “gold
standard” for measuring telomere length. Some conventional methods,
such as quantitative real-time PCR, may be more suitable to detect the
relationship between total telomere length and age-related risk factors,
as mentioned above (Wikgren et al., 2014). However, telomere HPA
does not require an electrophoresis or ampliﬁcation step and enables
a wide range of quantitative analysis (Tahara et al., 2005). In addition,
telomere HPA results are consistent with TRF analysis using Southern
blot in vitro and in vivo, as previously described (Anno et al., 2007).
Accordingly, we consider that telomere HPA is suitable for themeasure-
ment of telomere length in clinical samples. Regarding telomere G-tail
length, as described previously (Tahara et al., 2005), an appropriate
technique to accuratelymeasure G-tail length had not been established.
To solve this issue, we previously developed a telomere G-tail HPA
method (Tahara et al., 2005) which has the advantages of simple use,
accuracy, and high sensitivity for G-tails in vitro. Additionally, recently
we developed high-throughput automated machine for G-tail telomere
HPA that is applicable for clinical use (Hirashio et al., 2014). Telomere
G-tail HPA methods might therefore be more suitable for clinical use
than other G-tail length assays. In fact, the telomere G-tail HPA method
Table 4
Associations between vascular risk factors, laboratory ﬁndings and age-relatedwhitemat-
ter changes.
Age-related white matter changes
Spearman's
correlation
Multiple linear
regression
ρ P β coefﬁcient P
Age 0.376 b0.001 0.372 b0.001
Male 0.041 0.683 – –
Body mass index (kg/m2) 0.102 0.309 – –
Smoker 0.025 0.805 – –
Hypertension 0.263 0.008 – –
Diabetes mellitus 0.192 0.053 – –
Dyslipidemia −0.020 0.843 – –
Atrial ﬁbrillation −0.134 0.180 – –
Renal dysfunction 0.082 0.414 – –
Systolic blood pressure (mm Hg) 0.164 0.100 – –
Diastolic blood pressure (mm Hg) 0.004 0.971 – –
History of stroke 0.022 0.824 – –
History of coronary artery disease 0.101 0.313 – –
Laboratory ﬁndings
White blood cells (103/μl) −0.052 0.603 – –
HbA1c (%) 0.215 0.030 – –
FBG (mg/dl) 0.203 0.041 – –
LDL cholesterol (mg/dl) −0.039 0.701 – –
HDL cholesterol (mg/dl) −0.069 0.490 – –
TG (mg/dl) 0.063 0.532 – –
eGFR (ml/min/1.73 m2) −0.155 0.121 – –
hs-CRP, log (ng/ml) 0.043 0.670 – –
Telomere G-tail length (RLU/μg DNA) −0.309 0.002 −0.200 0.033
β coefﬁcient means standardized partial regression coefﬁcient.
FBG, fasting blood glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
TG, triglycerides; eGFR, estimated glomerular ﬁltration rate; RLU, relative light unit;
DNA, deoxyribonucleic acid.
966 T. Nezu et al. / EBioMedicine 2 (2015) 960–967has already been used to measure total telomere length and G-tail
length in practical clinical applications on a commercial clinical basis
(MiRTeL Co. LTD, Hiroshima, Japan).
In conclusion, telomere G-tail length might be a useful marker for
the severity of ARWMCs and endothelial function as evaluated by
FMD. A conclusive determination of the value of telomere G-tail length
in predicting the incidence of cerebral and cardiovascular events in
general populations awaits larger prospective studies.Sources of Funding
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